🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Perhaps the best and most caring cancer genomics mentor in the world to work with 👇

OncoKB™'s U.S. FDA tab is FDA Oncology recognized! A 3y journey & we couldn't be prouder to state we are the 1st somatic tumor mutation database w/ this accolade. OncoKB™ is the combined dedicated effort to sustain a knowledge base powered by @sloankettering clinical expertise.

Black men die from prostate cancer twice as often as White men. Dr. Brandon Mahal, Franklin Huang, Kosj Yamoah MD, PhD, and others have shown that tumors from Black men can be genomically different. Insights from Stopsack et al study out today Clinical Cancer Research. Prostate Cancer Foundation doi.org/10.1158/1078-0… 1/n

Proud to share our work out today in Nature Genetics. With Preethi Srinivasan, Michael Berger and Barry S. Taylor. nature.com/articles/s4158… We try to understand the extent to which cancers arising in patients with inherited pathogenic variants are actually mediated by the germline defect, 1/n

KIT+ MEK inhibition in GIST ➡️Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor ⭐️The best ORR was 69.0% William Tap Jon Trent, MD, PhD Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

In a phase II study of the KIT inhibitor imatinib plus the MEK inhibitor binimetinib as first-line therapy for advanced-stage GIST, the ORR was 69%, mPFS was 29.9 months and mOS was not reached; toxicity was manageable: ascopubs.org/doi/full/10.12… #stcsm #scmsm #medonc #caxtx

🚨 Breaking - Data from 25,000 patients is helping scientists at MSK's Sloan Kettering Institute answer — can a tumor's genetic mutations help predict whether and where cancer will spread? Cell Press Niki Schultz Francisco Sanchez-Vega Bastien Nguyen bit.ly/3uvXWFI

Online Now: Metastasis and organotropism: A look through the lens of large-scale clinical sequencing data dlvr.it/SJQ1K0

Read this week's Cancer Discovery #ResearchWatch Genomic Alterations Distinguish Patterns of Metastatic Dissemination by Niki Schultz, Francisco Sanchez-Vega, Bastien Nguyen, Chris Fong, @sloan_kettering. bit.ly/3oG7Ela

ASCO Provisional Clinical Opinion re Somatic Genomic Testing in pts w/ Metastatic or Adv Cancer is out! An honor to be on this boat captained by @MarkRobsonMD & Drs. Funda Meric-Bernstam w/ Dr. Amber Johnson. ascopubs.org/doi/full/10.12…

Our new @NCIHTAN paper has been published! It presents a unique spatial atlas of linked multimodal datasets from serial biopsies of a metastatic breast cancer evolving across multiple courses of therapy. 1/6 cell.com/cell-reports-m…

What a striking finding on questionable driver -- KRAS Q61K mutation. It seems like this is functional only when this coexists with adjacent silent mutation in G60 that abolishes cryptic splice site. Shocking deep biology from TKI resistance research. nature.com/articles/s4158…

new out in Nature, wonderful paper exploring the events in the first next cell cycle after whole genome duplication: nature.com/articles/s4158…

PIK3R1-mutation regulates Insulin-PI3K-glycolytic pathway in #prostatecancer. Our Clinical Cancer Research paper shows frequent oncogenic alteration of PIK3R1 in #mCRPC Phil Kantoff Subhi Nandakumar Niki Schultz PCF Science Memorial Sloan Kettering Cancer Center Mount Sinai Department of Urology aacrjournals.org/clincancerres/…

Our latest manuscript studying rectal cancer is out in Nature Medicine. This is work led by Julio Garcia Aguilar, Francisco Sanchez-Vega and myself, in collaboration with amazing colleagues at Memorial Sloan Kettering Cancer Center. 1/n nature.com/articles/s4159…

Featured today by MSK Library: Outcomes and Molecular Features of Brain Metastasis in...dx.doi.org/10.1001/jamane… Bastien Nguyen Anisha Luthra Joanne Chou Vivian E. Strong, MD Daniela ILSON David Darren Cowzer Niki Schultz Kathryn Beal, MD Nelson Moss Yelena Y. Janjigian MD Steve Maron

Tks anirban ! RNA seq and whole exome in 1000 and 500 pretreated metastatic cancers. Interesting to see the impact of prior therapies, especially platinum, on DNA + discovery of new alterations involved in resistance (PTEN transloc). A huge work from PRISM (maybe futur center🤞)